Poseida Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview
06/11/2024 13:49
* Poseida Therapeutics Inc PSTX.OQ PSTX.O is expected
to show
a rise in quarterly revenue when it reports results on November
7 (estimated) for the period ending January 1 0001
* The San Diego California-based company is expected to
report a
73.9% increase in revenue to $16.267 million from $9.35 million
a year ago, according to the mean estimate from 3 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for Poseida Therapeutics Inc
is
for a loss of 41 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Poseida
Therapeutics Inc is $12.00, above its last closing price
of $2.66.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.40 -0.41 -0.32 Beat 21.5
Jan. 1 2024 -0.42 -0.42 -0.25 Beat 40.5
Dec. 31 2023 -0.39 -0.39 -0.27 Beat 30.1
Sep. 30 2023 -0.30 -0.29 -0.35 Missed -19.7
Jun. -0.50 -0.53 -0.32 Beat 39.4
30 2023
Mar. 31 2023 -0.47 -0.45 -0.45 Met 0
Dec. 31 2022 -0.19 -0.22 -0.39 Missed -73.3
Sep. 30 2022 -0.63 -0.65 0.92 Beat 241
This summary was machine generated November 6 at 13:49 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)